Welcome to Penzberg. One of Europe s largest biotech facilities

Size: px
Start display at page:

Download "Welcome to Penzberg. One of Europe s largest biotech facilities"

Transcription

1 Welcome to Penzbeg One of Euope s lagest biotech facilities

2 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue

3 Whee it all began The Penzbeg site in 1957

4 Whee it all began The Penzbeg site in 1957 and 2004

5 The Penzbeg site today Founded: 1972 (Boehinge Mannheim) Aea: 310,000 m² Employees: 3,459 (Dec. 03) Invested capital: 870 Mill. (Dec. 03)

6 The Penzbeg site Headcount Numbe of employees *until 2000 incl. Tutzing

7 The Penzbeg site Employee qualifications Advanced taining 8% Technical college gaduates 9% Univesity gaduates 25% Vocational taining 53% unskilled 5%

8 The Penzbeg site Aveage age 38,5 38,4 38,5 38,4 38, * incl. Tutzing until 2000

9 The Penzbeg site Capital expenditue

10 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue

11 Penzbeg s Role Penzbeg is the only location woldwide whee both divisions have on-site eseach, development and poduction facilities Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction

12 Penzbeg s Role Biotechnology One of Euope s lagest Biotech facilities Lagest Biotech site in the Roche Goup Supplies poducts fo Diagnostics and Phamaceuticals Most Diagnostics poducts ae biotechnology based Poduces 4 impotant biophamaceuticals

13 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue

14 Roche Diagnostics Poduct potfolio Life Science Reseach in-vito diagnostics maket Reseach Pofessionals Consumes Applied Science Modula Analytics E 170 Molecula Diagnostics LightCycle Omni S Centalized Diagnostics Nea Patient Testing Accu-Chek Go Cobas Amplipep Diabetes Cae

15 Roche Diagnostics Regional headquates and R&D centes Bugdof Indianapolis Rotkeuz Basel Mannheim Penzbeg Gaz Applied Science Molecula Diagnostics Centalized Diagnostics leasanton/ Alameda Tokyo Nea Patient Testing Diabetes Cae Banchbug Regional headquates Bacelona Singapoe Copoate headquate

16 Penzbeg s Role Diagnostics R&D cente fo eagents in - clinical chemisty - immunology Cente of Excellence fo active ingedients (R&D and Poduction)

17 Biotechnology in Penzbeg Diagnostics Diagnostic eagents and systems Reseach eagents (e.g. estiction enzymes) Industial poducts (e.g. catalase) Enzyme tests (e.g. cholesteol) Immune tests (e.g. tumo makes) Nucleic acid diagnosis (e.g. HIV) Diabetes: Blood suga measuement Enzymes e.g. glucose oxidase

18 The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue

19 Penzbeg s Role Phamaceuticals Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction

20 The Roche Goup A global leade in biophamaceuticals Roche Goup 1st half 2004 MabThea/Rituxan NeoRecomon/Epogin Pegasys/Copegus Cellcept Heceptin Rocephin Xenical Xeloda Nutopin/Potopin Kytil geen: Biophamaceuticals Sales in CHF m Change H1/2004 vs. H1/ % + 3% + 142% + 19% + 26% + 0% + 0% - 11% + 10% + 13%

21 Penzbeg s Role Phamaceuticals One of 4 Roche s phamaceutical eseach centes Lagest eseach location fo oncology Cente of Excellence fo phamaceutical active ingedients

22 Phama Biologicals Penzbeg Biologicals Tech.Dev. and Manufactuing Biologicals Technical Development Biologicals R&D New Biologicals Manufactuing Biologicals Manufactuing

23 Roche global R&D centes Pleasanton Indianapolis Nutley Palo Alto Genentech Mannheim Penzbeg Penzbeg Basel Rotkeuz Basel RCMG Gaz Phama Biotechnology R&D Centes Chugai Phama Centes Diagnostics Centes Roche Goup

24 Biotechnology poduction in Penzbeg Phamaceuticals Active ingedients fo dugs: - Eythopoietin / Neoecomon - Recombinant plasminogen activato Rapilysin / eteplase - Tastuzumab / Heceptin - Peg-Intefeone-alpha 2a/ Pegasys - Ove 200 antibodies fo diagnostic tests - Active ingedients fo clinical studies Phama biotech poduction Appoved by FDA and EMEA

25 The Roche Goup s lagest biotech facility Site Penzbeg Pofile Role Diagnostics Phamaceuticals Futue

26 The Penzbeg site Biotechnology pojects Building 354 EPO (Eythopoietin) Investment: 182 m Completion: July 2005

27 The Penzbeg site Biotechnology pojects Building 345 Monoclonal antibodies fo Diagnostics Investment: 31.4 m Completion: Mach 2006

28 The Penzbeg site Biotechnology pojects Building 361/362 Bio Heceptin Investment: 290 m Completion: Decembe 07

The future challenges of Healthcare

The future challenges of Healthcare The futue challenges of Healthcae D. Eich Hunzike CFO F. Hoffmann La Roche Ltd. JPMogan Healthcae Confeence San Fancisco, Januay 12, 2005 This pesentation contains cetain fowad-looking statements. These

More information

Diabetes Care Beyond Meters and Strips

Diabetes Care Beyond Meters and Strips Diabetes Cae Beyond Metes and Stips R&D Day, May 2004 Staffan Ek Head of Diabetes Cae, Roche Diagnostics 1 Roche is well positioned in gowing maket segments Blood Glucose Monitoing maket size 7.3 bn CHF

More information

Shaping the future of diabetes care

Shaping the future of diabetes care Shaping the futue of diabetes cae 1 Heino von Pondzynski Head of Roche Diagnostics 2 The idea Roche Diagnostics, the woldwide leade in Diabetes monitoing, and Disetonics, the woldwide numbe 2-playe in

More information

The relevance of Roche s strategy in the current market environment

The relevance of Roche s strategy in the current market environment Maket dynamics in the Healthcae Industy The elevance of Roche s stategy in the cuent maket envionment D. F.B. Hume, CEO Bank am Bellevue, Januay 2005 This pesentation contains cetain fowad-looking statements.

More information

Significant value in diagnostic information

Significant value in diagnostic information U.S. Centalized Oveview Tom Adkins Vice Pesident Sales and Maketing Centalized, USA 1 Centalized Significant value in diagnostic infomation Diagnostic analysis of blood and othe body fluids pefomed in

More information

Presentation to analysts Basel, October 14, 2004. Roche YTD Sep '04 Sales, Oct 14, 2004

Presentation to analysts Basel, October 14, 2004. Roche YTD Sep '04 Sales, Oct 14, 2004 Roche Thid quate 2004 Pesentation to analysts Basel, Octobe 14, 2004 2 1 This pesentation contains cetain fowad-looking statements. These fowad-looking statements may be identified by wods such as believes,

More information

IT Risk Management. Agenda. Roche at a glance OSI Layers above 7 What we did What we plan to do how to not get shoot

IT Risk Management. Agenda. Roche at a glance OSI Layers above 7 What we did What we plan to do how to not get shoot IT Risk Management 30. 2006 ISACA Switzerland Chapter After Hours Seminar Mario Walter Agenda Roche at a glance OSI Layers above 7 What we did What we plan to do how to not get shoot 2006 ISACA After Hours

More information

Roche Diagnostics Positioned for growth

Roche Diagnostics Positioned for growth Roche Diagnostics Positioned fo gowth Heino von Pondzynski CEO Division Roche Diagnostics London, Septembe 9th, 2005 1 This pesentation contains cetain fowad-looking statements. These fowad-looking statements

More information

Equity compensation plans New Income Statement impact on guidance Earnings Per Share Questions and answers

Equity compensation plans New Income Statement impact on guidance Earnings Per Share Questions and answers Investos/Analysts Confeence: Accounting Wokshop Agenda Equity compensation plans New Income Statement impact on guidance Eanings Pe Shae Questions and answes IAC03 / a / 1 1 Equity compensation plans The

More information

Roche Diagnostics Leading and creating new markets

Roche Diagnostics Leading and creating new markets Roche Leading and ceating new makets Heino von Pondzynski Head of Roche Goldman Sachs UK Roadshow London, May 14 th 2004 This pesentation contains cetain fowad-looking statements. These fowad-looking statements

More information

Nine-month sales show continued double-digit growth significantly above the market average

Nine-month sales show continued double-digit growth significantly above the market average Investor Update Basel, 14 October 2004 Nine-month sales show continued double-digit growth significantly above the market average Roche Group Sales in core businesses up by 14%* to 21.9 billion Swiss francs

More information

Point of Care Testing market and Roche

Point of Care Testing market and Roche US Point of Cae Oveview Rod Cotton Vice Pesident and Geneal Manage Point of Cae, USA 1 Point of Cae Testing maket and Roche Stategy and futue dives 2 Roche US Event Cotton, Point-of-Cae 1 Point-of-Cae

More information

Focusing on differentiated medicines

Focusing on differentiated medicines Roche Phamaceuticals Focusing on diffeentiated medicines D. Guido Magni Head of Global Medical Science Lehman Bothes Global Healthcae Confeence, Miami, 26 1 This pesentation contains cetain fowad-looking

More information

CRRC-1 Method #1: Standard Practice for Measuring Solar Reflectance of a Flat, Opaque, and Heterogeneous Surface Using a Portable Solar Reflectometer

CRRC-1 Method #1: Standard Practice for Measuring Solar Reflectance of a Flat, Opaque, and Heterogeneous Surface Using a Portable Solar Reflectometer CRRC- Method #: Standad Pactice fo Measuing Sola Reflectance of a Flat, Opaque, and Heteogeneous Suface Using a Potable Sola Reflectomete Scope This standad pactice coves a technique fo estimating the

More information

Roche reports solid sales growth in the first quarter of 2016

Roche reports solid sales growth in the first quarter of 2016 Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increase

More information

Investor Update. Roche posts very strong interim results. Basel, 20 July 2005

Investor Update. Roche posts very strong interim results. Basel, 20 July 2005 Investor Update Basel, 20 July 2005 Roche posts very strong interim results Roche Group Group sales up 17%. Pharmaceutical sales grow three times faster than the global market Operating profit rises 30%,

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

Roche reports strong sales growth in the first quarter of 2015. medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair)

Roche reports strong sales growth in the first quarter of 2015. medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair) Media Release Basel, 22 April 2015 Roche reports strong sales growth in the first quarter of 2015 Group sales up 5% at constant exchange rates (CER) 1, 3% in Swiss francs Pharmaceuticals Division sales

More information

Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture

Diagnostics Division. Roland Diggelmann COO Roche Diagnostics. Picture Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture HY 2013: Roche Group highlights HY 2013 performance Strong Pharma performance, driven by US; solid growth for Diagnostics 12% core EPS

More information

Roche Interim results 2006. Roche Interim Results 2006 July 20, 2006 1

Roche Interim results 2006. Roche Interim Results 2006 July 20, 2006 1 r Roche Interim results 2006 London, July 20, 2006 July 20, 2006 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,

More information

Database Management Systems

Database Management Systems Contents Database Management Systems (COP 5725) D. Makus Schneide Depatment of Compute & Infomation Science & Engineeing (CISE) Database Systems Reseach & Development Cente Couse Syllabus 1 Sping 2012

More information

Evaluating the impact of Blade Server and Virtualization Software Technologies on the RIT Datacenter

Evaluating the impact of Blade Server and Virtualization Software Technologies on the RIT Datacenter Evaluating the impact of and Vitualization Softwae Technologies on the RIT Datacente Chistophe M Butle Vitual Infastuctue Administato Rocheste Institute of Technology s Datacente Contact: chis.butle@it.edu

More information

Three months ended 31 March

Three months ended 31 March Media Release Basel, 15 April 2010 Excellent growth in first quarter of 2010 Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars).

More information

Bettina Marcinkowski, Roche Diagnostics GmbH

Bettina Marcinkowski, Roche Diagnostics GmbH Roche an attractive employer Academic Recruiting, Career Services & Employer Branding Munich, February 27, 2012 Bettina Marcinkowski, Roche Diagnostics GmbH To share with you Passionate about recruiting

More information

We Innovate Healthcare

We Innovate Healthcare Part 2 Roche Annual Report 2006 Finance Report We Innovate Healthcare Innovation spanning the entire healthcare spectrum As a pharmaceuticals and a diagnostics company, Roche brings pioneering products

More information

Life writes the questions We pursue the answers

Life writes the questions We pursue the answers Life writes the questions We pursue the answers Life writes the questions. 1 What will help me? Can I have hope? When will the others notice? How much life is six months? How bad can it get? Am I alone?

More information

Channel selection in e-commerce age: A strategic analysis of co-op advertising models

Channel selection in e-commerce age: A strategic analysis of co-op advertising models Jounal of Industial Engineeing and Management JIEM, 013 6(1):89-103 Online ISSN: 013-0953 Pint ISSN: 013-843 http://dx.doi.og/10.396/jiem.664 Channel selection in e-commece age: A stategic analysis of

More information

The impact of migration on the provision. of UK public services (SRG.10.039.4) Final Report. December 2011

The impact of migration on the provision. of UK public services (SRG.10.039.4) Final Report. December 2011 The impact of migation on the povision of UK public sevices (SRG.10.039.4) Final Repot Decembe 2011 The obustness The obustness of the analysis of the is analysis the esponsibility is the esponsibility

More information

Epdf Sulf petroleum, Eflecti and Eeflecti

Epdf Sulf petroleum, Eflecti and Eeflecti ANALYSIS OF GLOBAL WARMING MITIGATION BY WHITE REFLECTING SURFACES Fedeico Rossi, Andea Nicolini Univesity of Peugia, CIRIAF Via G.Duanti 67 0615 Peugia, Italy T: +9-075-585846; F: +9-075-5848470; E: fossi@unipg.it

More information

Roche Finance Report Roche

Roche Finance Report Roche 2010 Roche Finance Report Table of contents Roche Group 2 Finance in brief 2 Finance 2010 in brief 3 Financial Review 4 Roche Group Consolidated Financial Statements 34 Notes to the Roche Group Consolidated

More information

A framework for the selection of enterprise resource planning (ERP) system based on fuzzy decision making methods

A framework for the selection of enterprise resource planning (ERP) system based on fuzzy decision making methods A famewok fo the selection of entepise esouce planning (ERP) system based on fuzzy decision making methods Omid Golshan Tafti M.s student in Industial Management, Univesity of Yazd Omidgolshan87@yahoo.com

More information

Drug Discovery in China

Drug Discovery in China Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China

More information

SNAPSHOT ASIA FIRST IN A SERIES OF REGIONAL SECTOR ANALYSES 2003 OCTOBER. Benchmarking FDI Competitiveness in Asia

SNAPSHOT ASIA FIRST IN A SERIES OF REGIONAL SECTOR ANALYSES 2003 OCTOBER. Benchmarking FDI Competitiveness in Asia FIRST IN A SERIES OF REGIONAL SECTOR ANALYSES 2003 OCTOBER Benchmaking FDI Competitiveness in Asia Copyight 2003 The Wold Bank Goup/MIGA 1818 H Steet, NW Washington, DC 20433 All ights eseved Manufactued

More information

Displacement, Velocity And Acceleration

Displacement, Velocity And Acceleration Displacement, Velocity And Acceleation Vectos and Scalas Position Vectos Displacement Speed and Velocity Acceleation Complete Motion Diagams Outline Scala vs. Vecto Scalas vs. vectos Scala : a eal numbe,

More information

Electricity transmission network optimization model of supply and demand the case in Taiwan electricity transmission system

Electricity transmission network optimization model of supply and demand the case in Taiwan electricity transmission system Electicity tansmission netwok optimization model of supply and demand the case in Taiwan electicity tansmission system Miao-Sheng Chen a Chien-Liang Wang b,c, Sheng-Chuan Wang d,e a Taichung Banch Gaduate

More information

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced

More information

We Innovate Healthcare

We Innovate Healthcare Part 2 Roche Annual Report 2007 Finance Report We Innovate Healthcare We Innovate Healthcare As a research-intensive healthcare company, Roche discovers, develops and provides innovative diagnostic and

More information

+0.1 +3.9 +5.9 +4.5 +1.4

+0.1 +3.9 +5.9 +4.5 +1.4 Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2012 +4.7 2011 +0.1 44.0 40.9 Diagnostics 2012 2011 +3.9 +5.9 21.3 22.4 Group 2012

More information

Magnetic Field and Magnetic Forces. Young and Freedman Chapter 27

Magnetic Field and Magnetic Forces. Young and Freedman Chapter 27 Magnetic Field and Magnetic Foces Young and Feedman Chapte 27 Intoduction Reiew - electic fields 1) A chage (o collection of chages) poduces an electic field in the space aound it. 2) The electic field

More information

883 Brochure A5 GENE ss vernis.indd 1-2

883 Brochure A5 GENE ss vernis.indd 1-2 ess x a eu / u e a. p o.eu c e / :/ http EURAXESS Reseaches in Motion is the gateway to attactive eseach caees in Euope and to a pool of wold-class eseach talent. By suppoting the mobility of eseaches,

More information

Automated Hydraulic Drilling Rigs. HHSeries

Automated Hydraulic Drilling Rigs. HHSeries Automated Hydaulic Dilling Rigs HHSeies The Shape of Things to Come CUSTOMSOLUTIONS HH600 Rig The HH Hydaulic Hoist Seies Eveything about the HH Seies is designed fo speed, safety and efficiency. You can

More information

Roche delivers continued growth in the first half of 2016

Roche delivers continued growth in the first half of 2016 Media Release Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales up

More information

Roche on track for full-year targets good sales growth in first quarter

Roche on track for full-year targets good sales growth in first quarter Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss

More information

IBM Research Smarter Transportation Analytics

IBM Research Smarter Transportation Analytics IBM Reseach Smate Tanspotation Analytics Laua Wynte PhD, Senio Reseach Scientist, IBM Watson Reseach Cente lwynte@us.ibm.com INSTRUMENTED We now have the ability to measue, sense and see the exact condition

More information

Key figures 2015 CHF millions % change

Key figures 2015 CHF millions % change Media Release Basel, 28 January 2016 Roche reports strong results in 2015 Group sales increased by 5% 1 at constant exchange rates, 1% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncology

More information

E.S.G. Risk Factors in a Portfolio Context

E.S.G. Risk Factors in a Portfolio Context .S.G. Risk Factos in a Potfolio Context Integated Modeling of nvionmental, Social and Govenance Risk Factos An Innovative Study fo Institutional Investos Novembe/Decembe, 2009 D. Steffen Höte isklab GmbH

More information

Distributed Computing and Big Data: Hadoop and MapReduce

Distributed Computing and Big Data: Hadoop and MapReduce Distibuted Computing and Big Data: Hadoop and Map Bill Keenan, Diecto Tey Heinze, Achitect Thomson Reutes Reseach & Development Agenda R&D Oveview Hadoop and Map Oveview Use Case: Clusteing Legal Documents

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

AFFILIATE MEMBERSHIP APPLICATION

AFFILIATE MEMBERSHIP APPLICATION Califonia Constuction Tucking Association AFFILIATE MEMBERSHIP APPLICATION Reach and Netwok with the Lagest Concentation of Constuction Tucking Fims in the U.S. Affiliate Dues - $500 Annual CCTA 334 N.

More information

Module Availability at Regent s School of Drama, Film and Media Autumn 2016 and Spring 2017 *subject to change*

Module Availability at Regent s School of Drama, Film and Media Autumn 2016 and Spring 2017 *subject to change* Availability at Regent s School of Dama, Film and Media Autumn 2016 and Sping 2017 *subject to change* 1. Choose you modules caefully You must discuss the module options available with you academic adviso/

More information

Risks for the Swiss Pharmaceutical Market in 2013

Risks for the Swiss Pharmaceutical Market in 2013 Media Release Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net income

More information

The LCOE is defined as the energy price ($ per unit of energy output) for which the Net Present Value of the investment is zero.

The LCOE is defined as the energy price ($ per unit of energy output) for which the Net Present Value of the investment is zero. Poject Decision Metics: Levelized Cost of Enegy (LCOE) Let s etun to ou wind powe and natual gas powe plant example fom ealie in this lesson. Suppose that both powe plants wee selling electicity into the

More information

New Mid-Term Business Plan Sunrise 2012

New Mid-Term Business Plan Sunrise 2012 New Mid-Term Business Plan Sunrise 2012 CHUGAI PHARMACEUTICAL CO.,LTD. President and CEO Osamu Nagayama January 30/31, 2008 Forward Looking Statements This presentation may include forward looking statements

More information

Concept and Experiences on using a Wiki-based System for Software-related Seminar Papers

Concept and Experiences on using a Wiki-based System for Software-related Seminar Papers Concept and Expeiences on using a Wiki-based System fo Softwae-elated Semina Papes Dominik Fanke and Stefan Kowalewski RWTH Aachen Univesity, 52074 Aachen, Gemany, {fanke, kowalewski}@embedded.wth-aachen.de,

More information

College of Engineering Bachelor of Computer Science

College of Engineering Bachelor of Computer Science 2 0 0 7 w w w. c n u a s. e d u College of Engineeing Bachelo of Compute Science This bochue Details the BACHELOR OF COMPUTER SCIENCE PROGRAM available though CNU s College of Engineeing. Fo ou most up-to-date

More information

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the Media Release Basel, 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms

More information

cover comparison TUH it s my health fund! Your Queensland health fund Effective 2 April 2014

cover comparison TUH it s my health fund! Your Queensland health fund Effective 2 April 2014 Effective 2 Apil 2014 You Queensland health fund cove compaison TUH it s my health fund! PLEASE CAREFULLY READ AND RETAIN THIS BROCHURE. PLEASE READ IN CONJUNCTION WITH THE Fine Points BROCHURE. waiting

More information

Ilona V. Tregub, ScD., Professor

Ilona V. Tregub, ScD., Professor Investment Potfolio Fomation fo the Pension Fund of Russia Ilona V. egub, ScD., Pofesso Mathematical Modeling of Economic Pocesses Depatment he Financial Univesity unde the Govenment of the Russian Fedeation

More information

How Much Should a Firm Borrow. Effect of tax shields. Capital Structure Theory. Capital Structure & Corporate Taxes

How Much Should a Firm Borrow. Effect of tax shields. Capital Structure Theory. Capital Structure & Corporate Taxes How Much Should a Fim Boow Chapte 19 Capital Stuctue & Copoate Taxes Financial Risk - Risk to shaeholdes esulting fom the use of debt. Financial Leveage - Incease in the vaiability of shaeholde etuns that

More information

Technology Launch from Seed Funding to Liquidity Event

Technology Launch from Seed Funding to Liquidity Event Technology Launch fom Seed Funding to Liquidity Event Tammi Smoynski Diecto, Intel Capital Intel Copoation Septembe, 2010 * Othe maks and bands ae popety of thei espective ownes Intel Capital Oveview Taditional

More information

Fixed Income Attribution: Introduction

Fixed Income Attribution: Introduction 18th & 19th Febuay 2015, Cental London Fixed Income Attibution: A compehensive undestanding of Fixed Income Attibution and the challenging data issues aound this topic Delegates attending this two-day

More information

YARN PROPERTIES MEASUREMENT: AN OPTICAL APPROACH

YARN PROPERTIES MEASUREMENT: AN OPTICAL APPROACH nd INTERNATIONAL TEXTILE, CLOTHING & ESIGN CONFERENCE Magic Wold of Textiles Octobe 03 d to 06 th 004, UBROVNIK, CROATIA YARN PROPERTIES MEASUREMENT: AN OPTICAL APPROACH Jana VOBOROVA; Ashish GARG; Bohuslav

More information

91,747 employees in over 100 countries

91,747 employees in over 100 countries Roche in Brief 2015 Roche Who we are Who we are Roche Who we are 91,747 employees in over 100 countries CHF 48.1 bn in Group sales in 2015 # 1 in biotech, oncology, in vitro diagnostics and hospital market

More information

ON THE (Q, R) POLICY IN PRODUCTION-INVENTORY SYSTEMS

ON THE (Q, R) POLICY IN PRODUCTION-INVENTORY SYSTEMS ON THE R POLICY IN PRODUCTION-INVENTORY SYSTEMS Saifallah Benjaafa and Joon-Seok Kim Depatment of Mechanical Engineeing Univesity of Minnesota Minneapolis MN 55455 Abstact We conside a poduction-inventoy

More information

CONCEPTUAL FRAMEWORK FOR DEVELOPING AND VERIFICATION OF ATTRIBUTION MODELS. ARITHMETIC ATTRIBUTION MODELS

CONCEPTUAL FRAMEWORK FOR DEVELOPING AND VERIFICATION OF ATTRIBUTION MODELS. ARITHMETIC ATTRIBUTION MODELS CONCEPUAL FAMEOK FO DEVELOPING AND VEIFICAION OF AIBUION MODELS. AIHMEIC AIBUION MODELS Yui K. Shestopaloff, is Diecto of eseach & Deelopment at SegmentSoft Inc. He is a Docto of Sciences and has a Ph.D.

More information

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition

More information

Table of Contents. Key figures 3

Table of Contents. Key figures 3 Key figures 3 Group and Divisional Results 4 Overview 4 Pharmaceuticals 5 Diagnostics 7 Vitamins and Fine Chemicals 7 Group operating results 8 Financial income 8 Cash flows 8 Financial condition 9 Outlook

More information

GESTÃO FINANCEIRA II PROBLEM SET 1 - SOLUTIONS

GESTÃO FINANCEIRA II PROBLEM SET 1 - SOLUTIONS GESTÃO FINANCEIRA II PROBLEM SET 1 - SOLUTIONS (FROM BERK AND DEMARZO S CORPORATE FINANCE ) LICENCIATURA UNDERGRADUATE COURSE 1 ST SEMESTER 2010-2011 Chapte 1 The Copoation 1-13. What is the diffeence

More information

MEDIA KIT Texas Aggregates & Concrete Association

MEDIA KIT Texas Aggregates & Concrete Association MEDIA KIT Texas Aggegates & Concete Association Solidify you band to membes who spend $350 million on poducts and sevices each yea. TACA Conveyo magazine pint & digital Membeship Diectoy & Resouce Guide

More information

FXA 2008. Candidates should be able to : Describe how a mass creates a gravitational field in the space around it.

FXA 2008. Candidates should be able to : Describe how a mass creates a gravitational field in the space around it. Candidates should be able to : Descibe how a mass ceates a gavitational field in the space aound it. Define gavitational field stength as foce pe unit mass. Define and use the peiod of an object descibing

More information

PlantForm Corporation

PlantForm Corporation PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more

More information

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area

Profile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many

More information

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols For questions on the content of this document contact Leonard Wilson, CBER at 301-827-0373 or Susan Johnson, CDER

More information

Roche delivers strong performance in the first half of 2015

Roche delivers strong performance in the first half of 2015 Media Release Basel, 23 July 2015 Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven

More information

An Introduction to Omega

An Introduction to Omega An Intoduction to Omega Con Keating and William F. Shadwick These distibutions have the same mean and vaiance. Ae you indiffeent to thei isk-ewad chaacteistics? The Finance Development Cente 2002 1 Fom

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Roland Diggelmann, COO Roche Diagnostics Bad Ragaz, 16 Jan 2015 Business model & strategy Q3 2014 overview Major products, launches and newsflow Building a leading sequencing

More information

TRADING DAYS IN 2010 - LONDON DERIVATIVES MARKET INTRODUCTION

TRADING DAYS IN 2010 - LONDON DERIVATIVES MARKET INTRODUCTION EURONEXT DERIVATIVES MARKETS LONDON MARKET TRADING DAYS IN 2010 - LONDON DERIVATIVES MARKET INTRODUCTION An oveview of the Tading Days in 2010 was issued unde London Notice No. 3203 on 13 Octobe 2009.

More information

WELCOME TO OUR NEW NEWSLETTER

WELCOME TO OUR NEW NEWSLETTER ISSUE ONE > JUNE 2013 WELCOME TO OUR NEW NEWSLETTER PARTNERS OUTLOOK Welcome to the band new Patnes Outlook newslette. It s had to believe it s June and anothe end of financial yea is aleady ceeping up.

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

Broad Selection of Antibodies & Antigens. for the Diagnostics Industry in North America

Broad Selection of Antibodies & Antigens. for the Diagnostics Industry in North America Broad Selection of Antibodies & Antigens for the Diagnostics Industry in North America Antibodies and Antigens for Diagnostics Diagnostics manufacturers require antibodies and antigens of proven quality

More information

Danish and European plans for wind energy deployment. Denmark has a goal of supplying 50% of its domestic power consumption from wind by 2020.

Danish and European plans for wind energy deployment. Denmark has a goal of supplying 50% of its domestic power consumption from wind by 2020. Downloaded fom obit.dtu.dk on: Feb 07 2016 Synthesis Lasen Hans Hvidtfdt; Søndebeg Petesen Leif Published in: DTU Intenational Enegy Repot 2014 Publication date: 2014 Document Vesion Publishe's PDF also

More information

Controlling the Money Supply: Bond Purchases in the Open Market

Controlling the Money Supply: Bond Purchases in the Open Market Money Supply By the Bank of Canada and Inteest Rate Detemination Open Opeations and Monetay Tansmission Mechanism The Cental Bank conducts monetay policy Bank of Canada is Canada's cental bank supevises

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Open Economies. Chapter 32. A Macroeconomic Theory of the Open Economy. Basic Assumptions of a Macroeconomic Model of an Open Economy

Open Economies. Chapter 32. A Macroeconomic Theory of the Open Economy. Basic Assumptions of a Macroeconomic Model of an Open Economy Chapte 32. A Macoeconomic Theoy of the Open Economy Open Economies An open economy is one that inteacts feely with othe economies aound the wold. slide 0 slide 1 Key Macoeconomic Vaiables in an Open Economy

More information

The Impact of Intel in Costa Rica

The Impact of Intel in Costa Rica The Impact of Intel in Costa Rica Nine Yeas Afte the Decision to Invest Investing in Development Seies Multilateal Investment Guaantee Agency 2006 Copyight 2006 The Wold Bank Goup/MIGA 1818 H Steet, NW

More information

INVESTIGATION OF FLOW INSIDE AN AXIAL-FLOW PUMP OF GV IMP TYPE

INVESTIGATION OF FLOW INSIDE AN AXIAL-FLOW PUMP OF GV IMP TYPE 1 INVESTIGATION OF FLOW INSIDE AN AXIAL-FLOW PUMP OF GV IMP TYPE ANATOLIY A. YEVTUSHENKO 1, ALEXEY N. KOCHEVSKY 1, NATALYA A. FEDOTOVA 1, ALEXANDER Y. SCHELYAEV 2, VLADIMIR N. KONSHIN 2 1 Depatment of

More information

Spirotechnics! September 7, 2011. Amanda Zeringue, Michael Spannuth and Amanda Zeringue Dierential Geometry Project

Spirotechnics! September 7, 2011. Amanda Zeringue, Michael Spannuth and Amanda Zeringue Dierential Geometry Project Spiotechnics! Septembe 7, 2011 Amanda Zeingue, Michael Spannuth and Amanda Zeingue Dieential Geomety Poject 1 The Beginning The geneal consensus of ou goup began with one thought: Spiogaphs ae awesome.

More information

How to SYSPREP a Windows 7 Pro corporate PC setup so you can image it for use on future PCs

How to SYSPREP a Windows 7 Pro corporate PC setup so you can image it for use on future PCs AnswesThatWok TM How to SYSPREP a Windows 7 Po copoate PC setup so you can image it fo use on futue PCs In a copoate envionment most PCs will usually have identical setups, with the same pogams installed

More information

YIELD TO MATURITY ACCRUED INTEREST QUOTED PRICE INVOICE PRICE

YIELD TO MATURITY ACCRUED INTEREST QUOTED PRICE INVOICE PRICE YIELD TO MATURITY ACCRUED INTEREST QUOTED PRICE INVOICE PRICE Septembe 1999 Quoted Rate Teasuy Bills [Called Banke's Discount Rate] d = [ P 1 - P 1 P 0 ] * 360 [ N ] d = Bankes discount yield P 1 = face

More information

NEW LONDON STATE PIER PROPERTY CHARACTERISTICS

NEW LONDON STATE PIER PROPERTY CHARACTERISTICS NEW LONDON STATE PIER PROPERTY CHARACTERISTICS PROPERTY CHARACTERISTICS The is situated in Southeasten, Connecticut appoximately 100 miles south of Boston, Massachusetts and 130 miles notheast of New Yok

More information

Biotechnology for the World The Roche site Penzberg

Biotechnology for the World The Roche site Penzberg Biotechnology for the World The Roche site Penzberg Kopfleiste zum ausfüllen 2 Biotechnology in Penzberg Research, development & production in Penzberg Penzberg Key site for biotech The Bavarian Roche

More information

Media release. Strong operating results for Roche in 2008. Basel, 4 February 2009

Media release. Strong operating results for Roche in 2008. Basel, 4 February 2009 Media release R Basel, 4 February 2009 Strong operating results for Roche in 2008 Double-digit sales growth * Core Earnings per share at constant exchange rates above 2007 level Dividend increase by 9%

More information

Contents. Overview 02 Who we are 04 What we do 06 2015 highlights 08 Chairman s shareholder letter 14 CEO s shareholder letter

Contents. Overview 02 Who we are 04 What we do 06 2015 highlights 08 Chairman s shareholder letter 14 CEO s shareholder letter Annual Report 2015 P A T I E N T S Positive late-stage clinical study results on our investigational medicine ocrelizumab in multiple sclerosis give hope to people living with this disease who need more

More information

INTEGRATION AND COMPETITION IN THE EUROPEAN FINANCIAL MARKETS * Juan Fernández de Guevara, Joaquín Maudos and Francisco Pérez **

INTEGRATION AND COMPETITION IN THE EUROPEAN FINANCIAL MARKETS * Juan Fernández de Guevara, Joaquín Maudos and Francisco Pérez ** INTEGRATION AN COMPETITION IN THE EUROPEAN FINANCIA MARKETS * Juan Fenández de Guevaa, Joaquín Maudos and Fancisco Péez ** WP-EC 2003-12 Coesponding autho: Joaquín Maudos, Instituto Valenciano de Investigaciones

More information

Software Engineering and Development

Software Engineering and Development I T H E A 67 Softwae Engineeing and Development SOFTWARE DEVELOPMENT PROCESS DYNAMICS MODELING AS STATE MACHINE Leonid Lyubchyk, Vasyl Soloshchuk Abstact: Softwae development pocess modeling is gaining

More information

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop

Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop Income Statement Format and Disclosures 2007 Conference call for Financial Analysts, November 2007 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements

More information

Media Release. Basel, 27 September 2015

Media Release. Basel, 27 September 2015 Media Release Basel, 27 September 2015 Two positive studies of Roche s investigational cancer immunotherapy atezolizumab in specific type of lung cancer presented at 2015 European Cancer Congress Phase

More information

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland 2016 All trademarks are legally protected. www.roche.com Roche Finance Report 2015 0 000 000 E Finance Report 2015 Finance in brief Key results Sales CER

More information

Application for Admission GENEVA COLLEGE

Application for Admission GENEVA COLLEGE Application fo Admission GENEVA COLLEGE 3 2 0 0 C o l l e g e A v e n u e, B e a v e F a l l s, P A 1 5 0 1 0 Application Instuctions When to apply You may apply fo admission any time afte you junio yea

More information